Leland Stanford Junior University

Corcept Therapeutics Incorporated

Akzo Nobel N.v.

The Board of Trustees of the Leland

Alan F Schatzberg

Joseph K Belanoff

Greer M Murphy

Richard M Myers

Huda Akil

Stanley Watson

Edward G Jones

Jun Li

Richard A Stein

Prabhakara V Choudary

Hiroaki Tomita

William E Bunney

Cortney Turner

Simon J Evans

Juan F Lopez

Robert C Thompson

Marquis P Vawter

Margherita Molnar

David M Lyons

Margit Burmeister

William E Bunny

William E Bunney, Jr

William E Bunney Jr

Devin Absher

René Bernard

David Michael Lyons

Cortney A Turner

Michael Boehnke

Laura J Scott

Fan Meng

Ilan Kerman

Rene Bernard

The present application relates to the treatment and diagnosis of mood disorders, including bipolar disorder, major depression disorder and schizophrenia. The invention provides novel diagnostic markers and assays, as well as research tools for the development and discovery of agents and compounds which are useful for treating patients who suffer from mental illness.

Methods for treating depression using NCAM peptide mimetics

The present invention provides methods for diagnosing mental disorders. The invention also provides methods of identifying modulators of mental disorders as well as methods of using these modulators to treat patients suffering from mental disorders.

Administration of FGF2 for treamtent of anxiety

A new method is found to determine an increased risk for side effects of an SSRI treatment in a person by genotyping the person for the presence of the 102 C/C DNA sequence in the 5-HTreceptor gene. This provides for a method to improve the treatment of an SSRI responsive disorder and in particular depression.

Method to determine the risk for side effects of an SSRI treatment in a person

This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to the glucocorticoid receptor can be used in methods of increasing the therapeutic response to electroconvulsive therapy ('ECT').

Methods for increasing the therapeutic response to electroconvulsive therapy

This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing antipsychotic-induced weight gain. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing AP-induced weight gain in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.

Methods for preventing antipsychotic-induced weight gain

This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating mild cognitive impairment. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating mild cognitive impairment in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.

Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist

This invention relates to methods for improving the therapeutic response of human patients with major depression by determining the apolipoprotein E genotype of a human patient and administering mirtazapine, in an amount effective to treat major depression, to those patients who are found to carry the gene for apolipoprotein E4. Also disclosed are methods for improving the therapeutic response of a human patient with major depression comprising administering mirtazapine, in an amount effective to treat major depression, to a human patient who is a carrier of the gene for apolipoprotein E4.

Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4

This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating dementia. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating dementa in a human including a glucoccrticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocoticoid receptor antagonist.

Methods for treating dementia

This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for ameliorating pathologies or conditions associated with psychosis. These pathologies or conditions include psychotic major depression, schizoaffective disorders, Alzheimer's Disease and cocaine addiction. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for the amelioration of psychosis in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.

Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists

This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for amelirating psychotic major depression. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods.

Methods for treating psychosis associated with glucocorticoid related

Growing community of inventors

Los Altos, CA, United States of America

Alan F Schatzberg